natgillin/translations-raw huggingface dataset:
In addition, a bioequivalence study was carried out in 24 healthy volunteers which showed that Neofordex has comparable quality to the reference medicine, Dectancyl. 
Poleg tega so opravili študijo biološke enakovrednosti pri 24 zdravih prostovoljcih, ki je pokazala, da je zdravilo Neofordex po kakovosti primerljivo referenčnemu zdravilu, zdravilu Dectancyl.
Neofordex must not be used in patients with active viral disease (especially hepatitis, cold sores, shingles or chicken pox) or with uncontrolled psychoses (altered sense of reality). 
Zdravila Neofordex ne smemo uporabljati pri bolnikih z aktivno virusno boleznijo (zlasti hepatitisom, herpesom na ustnici, pasovcem ali noricami) ali z nenadzorovanimi psihozami (spremenjenim občutkom za resničnost).
The most common side effects with Neofordex (which may affect more than 1 in 10 people) include hyperglycaemia (high blood sugar levels), insomnia (difficulty sleeping), muscle pain and weakness, asthenia (weakness), tiredness, oedema (swelling) and weight increase. 
Najpogostejši neželeni učinki zdravila Neofordex (ki lahko prizadenejo več kot 1 osebo od 10), vključujejo hiperglikemijo (povišano raven sladkorja v krvi), nespečnost (težave s spanjem), bolečine v mišicah in šibkost mišic, astenijo (šibkost), utrujenost, edem (otekanje) in povečanje telesne mase.
The usual dose is 40 mg once a day, taken preferably in the morning. 
Zdravilo Neofordex je na voljo v obliki tablet po 40 mg. Običajni odmerek je 40 mg enkrat na dan, najbolje zjutraj.
However, the dose and how frequently Neofordex is given varies depending on the medicines it is given with and the patient's condition. 
Odmerek in pogostnost dajanja zdravila Neofordex sta odvisna od zdravil, s katerimi se daje, in od bolnikovega stanja.
Other information about Neofordex 
Druge informacije o zdravilu Neofordex
For more information about treatment with Neofordex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Neofordex preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Neofordex has been shown to have comparable quality to Dectancyl and the use of high-dose dexamethasone in multiple meyloma is well established. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo dokazano, da je zdravilo Neofordex po kakovosti primerljivo zdravilu Dectancyl in da je uporaba deksametazona v velikem odmerku pri multiplem mielomu dobro uveljavljena.
Because the effects of high-dose dexamethasone in multiple myeloma are well established, the company for Neofordex presented studies from the literature on the use of dexamethasone for the treatment of multiple myeloma. 
Ker so učinki deksametazona v velikem odmerku pri multiplem mielomu dobro raziskani, je podjetje za zdravilo Neofordex predložilo študije iz literature o uporabi deksametazona za zdravljenje multiplega mieloma.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Neofordex, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Neofordex may also reduce certain side effects of cancer treatment, such as nausea (feeling sick) and vomiting. 
Zdravilo Neofordex lahko tudi zmanjša določene neželene učinke zdravil za zdravljenje raka, kot sta slabost (siljenje na bruhanje) in bruhanje.
Neofordex can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in the management of multiple myeloma. 
Izdaja zdravila Neofordex je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem multiplega mieloma.
Neofordex is a medicine used together with cancer medicines to treat adults with multiple myeloma who have developed symptoms. 
Neofordex je zdravilo, ki se uporablja skupaj z zdravili za zdravljenje raka pri odraslih z multiplim mielomom, pri katerih so se pojavili simptomi.
What benefits of Neofordex have been shown in studies? 
Kakšne koristi je zdravilo Neofordex izkazalo v študijah?
What is Neofordex and what is it used for? 
Kaj je zdravilo Neofordex in za kaj se uporablja?
What are the risks associated with Neofordex? 
Kakšna tveganja so povezana z zdravilom Neofordex?
The reference medicine for Neofordex is Dectancyl. 
Referenčno zdravilo za zdravilo Neofordex je zdravilo Dectancyl.
For practical information about using Neofordex, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Neofordex naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The active substance in Neofordex, dexamethasone, belongs to a group of medicines known as corticosteroids. 
Zdravilna učinkovina zdravila Neofordex, deksametazon, spada v skupino zdravil, znanih kot kortikosteroidi.
For the full list of all side effects reported with Neofordex, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Neofordex, glejte navodilo za uporabo.
Why is Neofordex approved? 
Zakaj je bilo zdravilo Neofordex odobreno?
In multiple myeloma, Neofordex is used together with cancer medicines to kill cancerous plasma cells. 
Pri multiplem mielomu se zdravilo Neofordex uporablja skupaj z zdravili za zdravljenje raka in tako uniči rakave plazemske celice.
It is not intended to provide practical advice on how to use Neofordex. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
How does Neofordex work? 
Kako zdravilo Neofordex deluje?
How is Neofordex used? 
Kako se zdravilo Neofordex uporablja?
Neofordex contains the active substance dexamethasone. 
Zdravilo Neofordex vsebuje zdravilno učinkovino deksametazon.
It is available as capsules (250 mg) and tablets (500 mg). 
Na voljo je v obliki kapsul (250 mg) in tablet (500 mg).
This makes them less effective at recognising and attacking the transplanted organ, lowering the risk of the organ being rejected. 
Ti so zato pri prepoznavanju in napadanju presajenega organa manj učinkoviti, kar zmanjšuje tveganje zavrnitve organa.
The dose may need to be adjusted in patients with liver or kidney disease. 
Odmerek bo morda treba prilagoditi pri bolnikih z obolenjem ledvic ali jeter.
This enzyme is important for the formation of DNA in cells, particularly in the lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants). 
Ta encim je pomemben pri nastajanju DNK v celicah, zlasti v limfocitih (vrsti belih krvnih celic, ki sodelujejo pri zavrnitvi presajenih organov).
It is used with ciclosporin and corticosteroids (other medicines used to prevent organ rejection). 
Uporablja se skupaj s ciklosporinom in kortikosteroidi (drugimi zdravili za preprečevanje zavrnitve organov).
The full EPAR for Mycophenolate mofetil Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Mycophenolate mofetil Teva je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For more information about treatment with Mycophenolate mofetil Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Mycophenolate mofetil Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In children aged between two and 18 years, the dose of Mycophenolate mofetil Teva is calculated depending on height and weight. 
Pri otrocih, starih od 2 do 18 let, se odmerek zdravila Mycophenolate mofetil Teva izračuna na podlagi telesne višine in mase.
This is a summary of the European public assessment report (EPAR) for Mycophenolate mofetil Teva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Mycophenolate mofetil Teva.
The European Commission granted a marketing authorisation valid throughout the European Union for Mycophenolate mofetil Teva on 21 February 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Mycophenolate mofetil Teva, veljavno po vsej Evropski uniji, odobrila dne 21. februarja 2008.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase'. 
V telesu se pretvori v mikofenolno kislino, ki zavira encim, imenovan „inozin monofosfatdehidrogenaza“.
This means that Mycophenolate mofetil Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called CellCept. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu CellCept.
The full EPAR for the reference medicine can also be found on the EMEA's website. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je prav tako na voljo na spletni strani agencije.
For heart transplants, the recommended adult dose is 1.5 g twice a day, starting within five days following the transplant. 
Pri presaditvi srca je priporočeni odmerek za odrasle bolnike 1,5 g zdravila dvakrat na dan, pri čemer je treba zdravilo začeti jemati v petih dneh po presaditvi.
Because Mycophenolate mofetil Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Mycophenolate mofetil Teva generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
The CHMP concluded that, in accordance with EU requirements, Mycophenolate mofetil Teva has been shown to have comparable quality and to be bioequivalent to CellCept. 
CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Mycophenolate mofetil Teva primerljivo raven kakovosti kot zdravilo CellCept ter da mu je biološko enakovredno.
The way that Mycophenolate mofetil Teva should be given and the dose depend on the type of organ transplant and the patient's age and size. 
Način uporabe zdravila Mycophenolate mofetil Teva in njegovo odmerjanje sta odvisna od vrste presajenega organa ter bolnikove starosti in velikosti.
For kidney transplants, the recommended dose in adults is 1.0 g twice a day starting within 72 hours after the transplant. 
Priporočeni odmerek za odrasle po presaditvi ledvice je 1,0 g dvakrat na dan, pri čemer je treba zdravilo začeti jemati v 72 urah po presaditvi.
For liver transplants in adults, mycophenolate mofetil should be given as an infusion (drip into a vein) for the first four days after the transplant, before the patient is switched to 1.5 g Mycophenolate mofetil Teva twice a day as soon as it can be tolerated. 
Pri odraslih bolnikih s presajenimi jetri se mofetilmikofenolat prve štiri dni po presaditvi daje kot infuzija (kapalna infuzija v veno), ko je bolnik sposoben požirati, pa preide na jemanje 1,5 g zdravila Mycophenolate mofetil Teva dvakrat na dan.
Therefore, the CHMP's view was that, as for CellCept, the benefit outweighs the identified risk. 
Zato je menil, da so njegove koristi, tako kot pri zdravilu CellCept, večje od znanih tveganj.
The Committee recommended that Mycophenolate mofetil Teva be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Mycophenolate mofetil Teva odobri dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mycophenolate mofetil Teva. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Mycophenolate mofetil Teva, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Mycophenolate mofetil Teva is used to prevent the body from rejecting a transplanted kidney, heart or liver. 
Zdravilo Mycophenolate mofetil Teva se uporablja za preprečevanje zavrnitve ledvic, srca ali jeter po presaditvi.
What are the benefits and risks of Mycophenolate mofetil Teva? 
Kakšne so koristi in tveganja, povezani z zdravilom Mycophenolate mofetil Teva?
Mycophenolate mofetil Teva is a ‘generic medicine'. 
Mycophenolate mofetil Teva je „generično zdravilo“.
Because Mycophenolate mofetil Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, CellCept. 
Ker je zdravilo Mycophenolate mofetil Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu CellCept.
Mycophenolate mofetil Teva treatment should be initiated and maintained by a qualified transplant specialist. 
Zdravljenje z zdravilom Mycophenolate mofetil Teva mora uvesti in voditi zdravnik specialist za presaditve.
Other information about Mycophenolate mofetil Teva 
Druge informacije o zdravilu Mycophenolate mofetil Teva:
Mycophenolate mofetil Teva is a medicine containing the active substance mycophenolate mofetil. 
Mycophenolate mofetil Teva je zdravilo, ki vsebuje zdravilno učinkovino mofetilmikofenolat.
By preventing the production of new DNA, Mycophenolate mofetil Teva reduces the rate at which the lymphocytes multiply. 
Zdravilo Mycophenolate mofetil Teva s preprečevanjem tvorbe nove DNK zmanjša hitrost razmnoževanja limfocitov.
Why has Mycophenolate mofetil Teva been approved? 
Zakaj je bilo zdravilo Mycophenolate mofetil Teva odobreno?
Mycophenolate mofetil Teva mycophenolate mofetil 
Mycophenolate mofetil Teva mofetilmikofenolat
The active substance in Mycophenolate mofetil Teva, mycophenolate mofetil, is an immunosuppressive medicine. 
Zdravilna učinkovina zdravila Mycophenolate mofetil Teva, mofetilmikofenolat, je zaviralec imunske odzivnosti.
How has Mycophenolate mofetil Teva been studied? 
Kako je bilo zdravilo Mycophenolate mofetil Teva raziskano?
What is Mycophenolate mofetil Teva? 
Kaj je zdravilo Mycophenolate mofetil Teva?
How is Mycophenolate mofetil Teva used? 
Kako se zdravilo Mycophenolate mofetil Teva uporablja?
What is Mycophenolate mofetil Teva used for? 
Za kaj se zdravilo Mycophenolate mofetil Teva uporablja?
• generalised anxiety disorder (long-term anxiety or nervousness about everyday matters). 
• splošno anksiozno motnjo (dolgotrajno anksioznostjo ali živčnostjo v zvezi s vsakdanjimi stvarmi).
Pregabalin Sandoz is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription. 
Zdravilo Pregabalin Sandoz je na voljo v obliki kapsul (25, 50, 75, 100, 150, 200, 225 in 300 mg) in se izdaja le na recept.
This reduces the activity of some of the nerve cells in the brain and spinal cord, reducing the release of other neurotransmitters that are involved in pain, epilepsy and anxiety. 
S tem se zmanjša dejavnost nekaterih živčnih celic v možganih in hrbtenjači, zaradi česar se zmanjša sproščanje drugih živčnih prenašalcev, ki so povezani z bolečino, epilepsijo in tesnobo.
• epilepsy, where it is used as an ‘add-on' to existing treatment in patients who have partial seizures (epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment; 
• epilepsijo, pri čemer se uporablja kot dodatek k obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptičnimi napadi, ki izvirajo iz določenega dela možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem;
The exact way that pregabalin works is not fully understood, but it is thought to affect the way that calcium enters nerve cells. 
Natančno delovanje pregabalina ni popolnoma jasno, vendar pa naj bi vplival na vstopanje kalcija v živčne celice.
The full EPAR and risk management plan summary for Pregabalin Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Pregabalin Sandoz sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Pregabalin Sandoz. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pregabalin Sandoz.
The European Commission granted a marketing authorisation valid throughout the European Union for Pregabalin Sandoz on 19 June 2015. 
Evropska komisija je dovoljenje za promet z zdravilom Pregabalin Sandoz, veljavno po vsej Evropski uniji, izdala 19. junija 2015.
Pregabalin Sandoz is a medicine used to treat adults with the following conditions: 
Pregabalin Sandoz je zdravilo, ki se uporablja za zdravljenje odraslih z naslednjimi boleznimi:
• neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with diabetes or herpes zoster (shingles), and central neuropathic pain, such as the pain experienced by patients who have had a spinal cord injury; 
• nevropatsko bolečino (bolečino zaradi poškodbe živcev), vključno s periferno nevropatsko bolečino, kot se pojavlja pri bolnikih z diabetesom ali pasovcem, in centralno nevropatsko bolečino, kot se pojavlja pri bolnikih s poškodbo hrbtenjače;
The Committee recommended that Pregabalin Sandoz be approved for use in the EU. 
Priporočil je, da se zdravilo Pregabalin Sandoz odobri za uporabo v EU.
What measures are being taken to ensure the safe and effective use of Pregabalin Sandoz? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pregabalin Sandoz?
This means that Pregabalin Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Lyrica. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Lyrica.
The active substance in Pregabalin Sandoz, pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects. 
Zdravilna učinkovina v zdravilu Pregabalin Sandoz, pregabalin, ima podobno strukturo kot telesu lastni „živčni prenašalec“ gama-aminomaslena kislina (GABA), vendar ima bistveno drugačne biološke učinke.
Pregabalin Sandoz is a ‘generic medicine'. 
Pregabalin Sandoz je „generično zdravilo“.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Sandoz has been shown to have comparable quality and to be bioequivalent to Lyrica. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pregabalin Sandoz primerljivo raven kakovosti kot zdravilo Lyrica ter da mu je biološko enakovredno.
After three to seven days, the dose can be increased to 300 mg per day. 
Po treh do sedmih dneh se lahko odmerek poveča na 300 mg na dan. Odmerki se lahko povečajo še do dvakrat, dokler ni dosežen najučinkovitejši odmerek.
For more information about treatment with Pregabalin Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Pregabalin Sandoz preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Because Pregabalin Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Pregabalin Sandoz generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
A risk management plan has been developed to ensure that Pregabalin Sandoz is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Pregabalin Sandoz je bil pripravljen načrt obvladovanja tveganj.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pregabalin Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
What are the benefits and risks of Pregabalin Sandoz? 
Kakšne so koristi in tveganja, povezani z zdravilom Pregabalin Sandoz?
For practical information about using Pregabalin Sandoz, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Pregabalin Sandoz naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Doctors may need to lower the dose in patients who have kidney problems. 
Pri bolnikih z ledvičnimi težavami bo zdravnik morda moral odmerek zmanjšati.
Stopping treatment with Pregabalin Sandoz should also be done gradually, over at least a week. 
Največji dovoljeni odmerek je 600 mg na dan. Tudi prenehanje zdravljenja z zdravilom Pregabalin Sandoz mora potekati postopno, in sicer mora trajati najmanj en teden.
Because Pregabalin Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Lyrica. 
Ker je zdravilo Pregabalin Sandoz generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Lyrica.
Other information about Pregabalin Sandoz 
Druge informacije o zdravilu Pregabalin Sandoz
What is Pregabalin Sandoz and what is it used for? 
Kaj je zdravilo Pregabalin Sandoz in za kaj se uporablja?
Why is Pregabalin Sandoz approved? 
Zakaj je bilo zdravilo Pregabalin Sandoz odobreno?
How has Pregabalin Sandoz been studied? 
Kako je bilo zdravilo Pregabalin Sandoz raziskano?
How is Pregabalin Sandoz used? 
Kako se zdravilo Pregabalin Sandoz uporablja?
It is not intended to provide practical advice on how to use Pregabalin Sandoz. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Pregabalin Sandoz contains the active substance pregabalin. 
Zdravilo Pregabalin Sandoz vsebuje zdravilno učinkovino pregabalin.
How does Pregabalin Sandoz work? 
Kako zdravilo Pregabalin Sandoz deluje?
20ml (10 mg/ml) 3 vials 
200 mg Koncentrat za raztopino za infundiranje intravenska uporaba viala (steklena) 20 ml (10 mg/ml) 3 viale
Pharmaceutical form 
Jakost farmacevtska oblika
Annex I List of nationally authorised medicinal products 
Priloga I Seznam nacionalno odobrenih zdravil
PARATABS RETARD PARACETAMOL 500MG TABLET 
PARATABS RETARD PARACETAMOL 500 MG TABLETE
PARACETAMOL 650MG TABLET, TRAMADOL 75MG TABLET 
PARACETAMOL 650 MG TABLETE, TRAMADOL 75 MG TABLETE
ATPALAIDAVIMO TABLETĖS 
VABASTAVAD TABLETID
DORETA 75 MG/650 MG PAILGINTO 
KRKA, D.D., NOVO MESTO DORETA 75 MG/650 MG PAILGINTO
[the below currently approved indications should be deleted (specific wording of the indication may vary from product to product)] 
[trenutno odobrene spodaj navedene indikacije je treba izbrisati (specifični vrstni red besed pri navajanju indikacij se lahko med posameznimi izdelki razlikuje)]
• Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia) 
• Simptomatsko zdravljenje kroničnih, patoloških, kognitivnih in nevrosenzoričnih obolenj pri starejših osebah (razen Alzheimerjeve bolezni in drugih oblik demence)
• Ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin 
• Pomožno zdravljenje zmanjšane ostrine vida in motnje vidnega polja, domnevno žilnega izvora